Provided by Tiger Trade Technology Pte. Ltd.

HUTCHMED

21.040
-0.740-3.40%
Volume:5.58M
Turnover:117.34M
Market Cap:18.35B
PE:5.16
High:21.780
Open:21.780
Low:20.840
Close:21.780
52wk High:28.800
52wk Low:15.570
Shares:872.00M
HK Float Shares:872.00M
Volume Ratio:0.40
T/O Rate:0.64%
Dividend:- -
Dividend Rate:- -
EPS(LYR):4.078
ROE:1.46%
ROA:-1.24%
PB:1.86
PE(LYR):5.16
PS:4.26

Loading ...

CICC Lifts HUTCHMED Price Target to HK$28, Reaffirms Outperform Rating

Stock News
·
Sep 08

UBS Flags Strong H1 Sales for Chinese Biotech Despite Regulatory Headwinds, Eyes Late-Year Catalysts

Stock News
·
Sep 07

Citigroup Lifts HUTCHMED Price Target to HK$39, Maintaining Buy and High-Risk Call

Stock News
·
Sep 04

HUTCHMED Surges Over 6% on $1.295 Billion GSK Deal, Validating Global Potential of Its ATTC Platform

Stock News
·
Sep 04

Movement Alert|HUTCHMED Rises 5.3% in Regular Trading, GSK Licensing Deal Worth Up to $1.295 Billion Continues to Lift Shares

Market Focus
·
Sep 04

HUTCHMED Surges 14% on $1.295 Billion Licensing Deal with GSK for Novel Dual-Targeting Cancer Therapy

Deep News
·
Sep 03

Asian Market Selloff Triggered by Yen Rally While Precious Metals Rebound Lifts Mining Sector

Stock News
·
Sep 03

Hong Kong Stocks Fall on Thursday, Amid Bond Selloff, Rate Fears; HUTCHMED Jumps 14%

MT Newswires Live
·
Sep 03

Hutchmed Jumps Most in Near 4 Years on GSK Licensing Deal

Reuters
·
Sep 03

UK Stocks-Factors to Watch on September 3

Reuters
·
Sep 03

Hutchmed China Ltd - Hutchmed Licenses Kras-Egfr-Antibody to GSK

THOMSON REUTERS
·
Sep 03

Sweden's Integrum Q1 Sales Rise on Higher S1 Surgeries

Reuters
·
Sep 03

Movement Alert|HUTCHMED Rises 8.36% in Regular Trading, Signs Global Licensing Agreement with GSK for KRAS-Targeted Antibody Drug Conjugate

Market Focus
·
Sep 03

Hutchmed (China) Signs Exclusive Licensing Deal with GSK for Investigational Cancer Drug

Reuters
·
Sep 03

HUTCHMED Grants GSK Ex-China Rights to KRAS-EGFR ATTC in Deal Worth Up to US$1.30 Billion

Bulletin Express
·
Sep 03

Hutchmed (China) - to Start Global Phase 1 Development Program in H2 2026

THOMSON REUTERS
·
Sep 03

Hutchmed Licenses KRAS-EGFR Antibody Conjugate HMPL-A830 to GSK for USD 110 Million Upfront

Reuters
·
Sep 03

Hutchmed (China) - Agreement Includes $110 Mln Upfront, up to $1.30 Bln in Milestones, Plus Royalties

THOMSON REUTERS
·
Sep 03

Hutchmed Announces Licensing Agreement with GSK for Kras-Egfr-Antibody Conjugate Cancer Therapy

THOMSON REUTERS
·
Sep 03

Hong Kong Stocks Edge Lower on Monday Amid Middle East Tensions; HUTCHMED Falls 2%

MT Newswires Live
·
Aug 31